Table 1.

Characteristics of patients with RA-ILD treated with RTX

Male sex, n (%)	16 (61.5)
Age at first RTX infusion, mean (SD), years	61.4 (6.5)
RA disease duration at first RTX, median (Q1-Q3), years	10.1 (4.3-29.7)
ILD disease duration at first RTX, median (Q1-Q3), years	1.9 (0.1-4.5)
Age at RA diagnosis, mean (SD), years	48.9 (14.0)
Age at ILD diagnosis, mean (SD), years	58.4 (7.3)
RF positivity	25 (96.2)
ACPA positivity*	20 (90.9)
ANA positivity†	11 (42.3)
Higher CRP (> 5 mg/L), n (%)	19 (73.1)
CRP levels,mg/L, mean (SD)	35.7 (52.9)
Higher ESR (>20 mm/hour), n (%)	21 (80.8)
ESR levels, mean (SD)	39.4 (18.0)
Smoking status‡, n (%)	16 (64.0)
Never	9 (37.5)
Ex-smoker	11 (45.8)
Current	4 (16.7)
Secondary Sjögren’s syndrome, n (%)	2 (7.7)
Prior anti-TNF treatment, n (%)	4 (15.4)
Concomitant DMARDs
Methothrexate	3 (11.5)
Azathioprine	1 (3.8)
Leflunomide	12 (46.2)
Mycophenolate mofetil	3 (11.5)
Steroids	24 (92.3)
DAS28 at first RTX infusion, mean (SD)	5.2 (1.5)
Radiographic pattern, n (%)
Usual interstitial pneumonia	11 (42.3)
Non-specific interstitial pneumonia	10 (38.5)
Organizing pneumonia	2 (7.7)
Indeterminate	3 (11.5)
Median pre-RTX DLCO ¥ , %, (Q1-Q3)	71.5 (51.0-79.8)
Median pre-RTX FVC § , %, (Q1-Q3)	76.5 (61.0-97.5)
Follow-up duration, median (Q1-Q3), years	2.5 (1.2-3.7)

RA= rheumatoid arthritis, ILD= interstitial lung disease, RTX= rituximab, RF= romatoid factor, ACPA= anti-citrullinated protein antibody, CRP= C reactive protein, ESR= erythrocyte sedimentation rate, anti-TNF= anti tumor necrosis factor, DMARDs= disease-modifying antirheumatic drugs, DAS28= disease activity score 28, DLCO= diffusion capacity of carbon monoxide, FVC= forced vital capacity *Data of 22 patients were available, †Data of 24 patients were available, ‡Data of 25 patients were available, ^¥Data of 18 patients were available, ^§Data of 16 patients were available